Tenofovir induced Fanconi syndrome: A possible pharmacokinetic interaction

被引:8
作者
Kapadia, Jigar [1 ]
Shah, Samidh [1 ]
Desai, Chetna [1 ]
Desai, Mira [1 ]
Patel, Shivani [2 ]
Shah, Asha N. [3 ,4 ]
Dikshit, R. K. [1 ]
机构
[1] BJ Med Coll, Dept Pharmacol, Ahmadabad, Gujarat, India
[2] BJ Med Coll, Dept Med, Ahmadabad, Gujarat, India
[3] Civil Hosp, Dept Med, Ahmadabad, Gujarat, India
[4] Civil Hosp, Nodal Officer ART Ctr, Ahmadabad, Gujarat, India
关键词
Adverse drug reaction; Fanconi syndrome; protease inhibitor; tenofovir; ADVERSE DRUG-REACTIONS; THERAPY;
D O I
10.4103/0253-7613.108319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tenofovir was introduced as a second line drug for the treatment of human immunodeficiency virus (HIV) infection in India in December 2009. Although rare, renal toxicity is a recognized adverse drug reaction (ADR) of this drug, especially when administered with boosted lopinavir-ritonavir. In this case, an HIV positive patient receiving tenofovir based antiretroviral therapy (ART) for last 1 year developed albuminuria, glycosuria and hypophosphatemia. Renal function tests and random blood sugar were within normal limits. He was diagnosed as a case of tenofovir induced Fanconi syndrome. Tenofovir was discontinued and patient was prescribed an alternate regimen. Five months later clinical symptoms and renal functions returned to normal. A pharmacokinetic interaction between tenofovir and ritonavir may have resulted in the toxicity. A periodic monitoring of renal functions is desirable in patients on tenofovir based ART.
引用
收藏
页码:191 / 192
页数:2
相关论文
共 11 条
[1]  
Asplin JR, 2005, HARRISONS PRINCIPLES, P1701
[2]  
Flexner C, 2006, PHARMACOL BASIS THER, P1290
[3]   Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy [J].
Goicoechea, Miguel ;
Liu, Shanshan ;
Best, Brookie ;
Sun, Shelly ;
Jain, Sonia ;
Kemper, Carol ;
Witt, Mallory ;
Diamond, Catherine ;
Haubrich, Richard ;
Louie, Stan .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (01) :102-108
[4]   PREVENTABILITY AND SEVERITY ASSESSMENT IN REPORTING ADVERSE DRUG-REACTIONS [J].
HARTWIG, SC ;
SIEGEL, J ;
SCHNEIDER, PJ .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (09) :2229-2232
[5]   Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy [J].
Jullien, V ;
Tréluyer, JM ;
Rey, E ;
Jaffray, P ;
Krivine, A ;
Moachon, L ;
Lillo-Le Louet, A ;
Lescoat, A ;
Dupin, N ;
Salmon, D ;
Pons, G ;
Urien, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3361-3366
[6]   Acquired Fanconi's syndrome associated with tenofovir therapy [J].
Mathew, George ;
Knaus, Stephen J. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 (11) :C3-C5
[7]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[8]  
Patel Ketan K, 2010, Indian J Sex Transm Dis AIDS, V31, P30, DOI 10.4103/0253-7184.68998
[9]   Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome:: The role of lopinavir-ritonavir-didanosine [J].
Rollot, F ;
Nazal, EM ;
Chauvelot-Moachon, L ;
Kélaïdi, C ;
Daniel, N ;
Saba, M ;
Abad, S ;
Blanche, P .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (12) :E174-E176
[10]  
Schumock G T, 1992, Hosp Pharm, V27, P538